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Abstract 
Taurine is a natural amino acid present as free form in many mammalian tissues and in particular in skeletal muscle. 
Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective 
effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and 
ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear 
mechanisms. This review summarizes the effects of taurine on specific muscle targets and pathways as well as its ther-
apeutic potential to restore skeletal muscle function and performance in various pathological conditions. Evidences 
support the link between alteration of intracellular taurine level in skeletal muscle and different pathophysiological 
conditions, such as disuse-induced muscle atrophy, muscular dystrophy and/or senescence, reinforcing the inter-
est towards its exogenous supplementation. In addition, taurine treatment can be beneficial to reduce sarcolemmal 
hyper-excitability in myotonia-related syndromes. Although further studies are necessary to fill the gaps between ani-
mals and humans, the benefit of the amino acid appears to be due to its multiple actions on cellular functions while 
toxicity seems relatively low. Human clinical trials using taurine in various pathologies such as diabetes, cardiovascular 
and neurological disorders have been performed and may represent a guide-line for designing specific studies in 
patients of neuromuscular diseases.
Keywords: Taurine skeletal muscle, Inherited muscle disorders, Disuse muscle atrophy, Development and aging, 
Skeletal muscle performance
© 2015 De Luca et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Taurine (2-aminoethane-sulfonic acid) is a sulfur-con-
taining amino acid which is not used for protein synthe-
sis and is therefore the most abundant free amino acid in 
mammalian tissues, with the exception of human liver 
in which aspartate is the most abundant one [1, 2]. The 
intracellular concentration of taurine ranges between 
5 and 20  µmol/g wet weight in many tissues, especially 
in excitable ones, such as brain, heart and skeletal mus-
cle [1, 3, 4]. Endogenous synthesis occurs in the liver via 
the cysteine sulfinic acid pathway. The metabolic reac-
tion consists in a first oxidation of the sulfhydryl group of 
cysteine to cysteine sulfinic acid by the enzyme cysteine 
dioxygenase. Cysteine sulfinic acid is then decarboxylated 
to hypotaurine by the cystyeine sulfinate decarboxylase. 
Taurine is obtained by a yet unclear spontaneous or 
enzymatic oxidation (by hypotaurine dehydrogenase) of 
hypotaurine (Fig.  1). The endogenous synthesis of tau-
rine is highly variable between individuals also in rela-
tion to nutritional state, to the amount of protein intake 
and to cysteine availability [1, 5]. In turn the availability 
of cysteine is highly dependent on the metabolic equi-
librium between homocysteine and methionine, via 
folic acid, vitamin B12 and the efficiency of the enzyme 
methyltetrahydrofolate reductase. In addition, a cer-
tain amount of taurine has to be introduced with food, 
mostly in carnivores and, to a minor extent, in omnivores 
[1]. The importance of the two sources vary quite a lot 
between species, with some, like felines and foxes, being 
highly dependent on diet acquisition of taurine, as they 
are unable to synthesize it. These species are also par-
ticularly susceptible to deficient states, developing severe 
pathophysiological conditions, such as dilated cardio-
myopathy, retinal degeneration and reproduction defects 
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[3, 6]. These evidences first outlined the key role of tau-
rine for mammalian tissue functions and helped to better 
understand the link between tissue distress in retaining 
proper taurine concentration and various pathophysi-
ological conditions.
In fact, even in species able to synthesize taurine, the 
tissue-specific synthesis is relatively low, with liver being 
the main source according to the higher expression of 
enzymes as cysteine dioxygenase. Importantly, the activ-
ity of this latter enzyme strictly depends upon cysteine 
availability, so that the exact amount of taurine being 
endogenously synthesized is difficult to predict [7]. How-
ever, the high intracellular concentration is guaranteed 
by the presence of a specific active transporter that con-
centrates taurine inside the cells against gradients. The 
taurine transporter (TauT; encoded by the SLC6A6 gene) 
is a sodium and chloride ion-dependent transporter 
ubiquitously expressed in mammalian tissues. The con-
centration of taurine is 100-fold less in the plasma (20–
100 µM) than in the tissues, suggesting that it is indeed 
required for modulating key cellular functions. Due to 
the high tissue concentration, taurine also works as an 
osmolyte. Its cellular efflux via volume-dependent or vol-
ume-independent pathways works to osmotically balance 
the excessive production of metabolic by-products. Both 
uptake systems and efflux pathways are tightly regulated 
at transcriptional and post-transcriptional level, leading 
to an accurate control of taurine intracellular levels [8].
Since its discovery in ox bile in 1827, several physio-
logical functions have been described for the amino acid, 
ranging from the classical role of conjugating agent for 
bile acids, to wider actions as osmotic pressure regula-
tor, modulator of calcium homeostasis and signaling and, 
more recently, as an endogenous anti-oxidant and anti-
inflammatory compound in various tissues. The mecha-
nism by which taurine exerts all these different functions 
is still unclear. Some of the taurine actions in central 
nervous system (CNS), seem to occur via specific bind-
ing sites or receptors, i.e. in thalamus taurine modulates 
neuronal firing via activation of extra-synaptic gamma-
amino butyric acid (GABA) receptor isoforms α4β2δ with 
a greater affinity than GABA [9–12]. Such high affinity 
binding sites have not been evidenced in other tissues.
Skeletal muscle is one of the tissues able to concentrate 
the largest amount of body’s taurine, via the TauT activ-
ity. Pioneer studies of Ryan Huxtable anticipated that 
the high taurine level is needed to maintain an appro-
priate calcium homeostasis, likely by ensuring a correct 
calcium re-uptake by the sarcoplasmic reticulum [13]. 
Similar actions were also described in heart, with taurine 
exerting complex modulation of calcium homeostasis in 
relation to external concentration of the cation with ben-
eficial effects in contrasting arrhythmias or heart failure 
[1, 3, 4].
Transgenic mice lacking TauT gene have been gener-
ated by two separate groups [6, 14–16]. In line with a 
key role of taurine for maintaining proper physiological 
functions, the drastic reduction in content consequent 
to TauT deletion is associated to a variety of disorders 
in various tissues, such as eye, kidney, heart, nociceptive 
system and skeletal muscle [14–17]. These conditions 
resemble those occurring when taurine tissue content is 
Fig. 1 Biosynthetic route of taurine from amino acids cystein and methionine. The synthesis does primarily occur in liver, although other tissues can 
contribute to its synthesis based on presence of key enzymes. However, the tissue synthesis is generally low, and tissues needs to uptake circulating 
taurine against gradients by means of the specific Na+/Cl− dependent transport system, TauT. Some species (i.e. felines) cannot synthesize taurine 
and dramatically depends on taurine intake with food. Diet is indeed an important source of the amino acid for all species, especially if reach of fish 
or beef meat as well as other animal-derived food (i.e. milk).
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altered by pathophysiological states or by inhibitors of 
the taurine transporter. In spite the pre-clinical research 
has disclosed many conditions in which taurine supple-
mentation may be beneficial, the therapeutic use of tau-
rine is very limited. Taurine is commonly known for its 
claimed effects as energizer and anti-fatigue compound 
and it is present in many energy soft drinks as well as in 
supplement cocktails for athletes. The toxicity of taurine 
in this context is considered relatively low with respect to 
other active ingredients; actually it may also be protec-
tive against cardiovascular action of caffeine [18]. Such 
a protection may again result from multiple taurine 
actions, i.e. an antihypertensive effect via vasodilatation 
(by reducing adrenergic and angiotensin II actions as well 
as calcium-induced vasospasm) along with a reduced risk 
of cardiac arrhythmias via modulation of ion channels 
and ionic homeostasis [18]. However a certain caution 
is important especially when taurine is used in children 
and/or in association with drugs, alchool or other food 
supplements [19–23]. Apart for its nutraceutical role, 
taurine may exert clear pharmacological actions by mod-
ulating signaling pathways and targets or via restoration 
of its altered tissue levels. No systematic toxicity studies 
have been performed to assess the toxicological param-
eters for taurine; however human trials have used taurine 
up to 10 g/daily without overt signs of toxicity. This may 
also depend on the direct relationship between taurine 
plasma level and its excretion rate by the kidney [19].
An extensive revision of all the actions of taurine in 
various tissues and the wide potential usefulness of its 
supplementation is out of the scope of this review. How-
ever, a general overview is provided in Fig.  2. As far as 
inherited or acquired pathophysiological conditions of 
skeletal muscle are concerned, the pre-clinical findings 
allow to distinguish effects related to exogenous phar-
macological action of taurine on rather specific targets, 
such as in myotonic syndromes, to conditions that may 
be accompanied by changes in intercellular taurine con-
tent or change in calcium homeostasis, in which a taurine 
supplementation may be helpful to restore altered levels.
Fig. 2 Taurine plays many and different physiological roles in various tissues. Some taurine actions, as the inhibitory effect at CNS, seem to be 
mediated by a receptor mechanism, while the effects on other tissues and systems occur via less defined mechanisms of action. Accordingly, the 
figure also briefly summarizes the main taurine effects ranging from control of calcium handling mechanism and excitation–contraction coupling 
in the heart, the ability to control immune reaction and inflammation, via inhibition of NF-kB as well as the main role of taurine in conjugating bile 
salts. Virtually all tissues are sensitive to taurine action with described effect of taurine on visual function (not shown), fertility, insulin release etc. The 
reported scheme is not supposed to be exhaustive of all taurine effects and only serves as general overview.
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The present review is aimed at providing the state-of-
art of taurine research in skeletal muscle, with particu-
lar attention to its potential therapeutic application as 
orphan drug in inherited rare muscle disorders, as well as 
in pathophysiological conditions such as aging, malnutri-
tion and/or muscle disuse.
Skeletal muscle ion channels as specific targets 
of taurine: the potential action of taurine 
as anti‑myotonic drug
Taurine and skeletal muscle chloride channels ClC‑1
In CNS, taurine has been long claimed to act as an “inhib-
itory” amino acid and neurotransmitter [1]. Neuronal 
synthesis of taurine and metabotropic taurine receptors 
have been described in specific areas of CNS, where tau-
rine acts in a glycine or GABA-like manner, by enhanc-
ing hyperpolarizing chloride-mediated conductance 
in nervous cells [9, 11, 12]. Pre-clinical evidences were 
provided of a beneficial effect of taurine in controlling/
preventing seizure discharges and neurotoxicity [1, 12, 
24]. The ability of taurine to act as inhibitory amino acid 
raised attention to its possible effect as potential mem-
brane stabilizer in skeletal muscle. We investigated about 
the actions of the amino acid on voltage-gated chloride 
channels CLC-1 that account for the macroscopic chlo-
ride conductance (gCl) of skeletal muscle. Resting gCl 
accounts for about 70–90% to the total membrane con-
ductance of sarcolemma and plays a pivotal role in main-
taining the sarcolemmal electrical stability by shunting 
the depolarization-driven potassium accumulation in 
transverse tubules. Thus the large gCl allows repolariza-
tion and muscle relaxation.
Loss-of-function mutations of CLC-1 are responsible 
of myotonic syndromes with either autosomal dominant 
(Thomsen disease) or recessive pattern of inheritance 
(Becker’s Myotonia Congenita). The resulting decrease of 
gCl is responsible for the pathological hyperexcitability 
and for the delayed relaxation, spasms and stiffness typi-
cal of the disease in both patients and myotonic animals 
[25–27].
Our research has shown that taurine, acutely applied 
in vitro, exerts a concentration-dependent increase of gCl 
in rat extensor digitorum longus (EDL) myofibers, and 
in parallel reduces membrane excitability [28, 29]. The 
effective concentrations are in the millimolar range, likely 
in relation to the high intracellular level of the amino 
acid [28, 29]. A pre-clinical evaluation of the potential 
anti-myotonic activity of taurine has been performed. 
We found that taurine does not antagonize the myotonic 
discharges in rats made myotonic by administration of 
anthracene-9-carboxylic acid, a direct chloride chan-
nel blocker, nor does it restore gCl lowered in  vitro by 
the same agent. However, when rats are made myotonic 
by a chronic exposure to 20,25 diazacholesterol, which 
reduces gCl indirectly by modifying lipid membrane 
composition, taurine antagonizes the electromyographic 
signs of myotonia if administered in vivo, while its acute 
in  vitro application contrasts both the reduced gCl and 
the high frequency firing of single myofibers [30]. These 
results suggested that taurine can contrast myotonia if 
chloride channels are available for a direct modulation, 
implying its direct action at channel level or on a site 
nearby. A series of taurine analogues were tested on gCl 
of rat EDL myofibers to investigate the structure–activity 
relationship (SAR) between taurine and chloride chan-
nels. The results provided a pharmacological evidence of 
the presence of a specific low-affinity taurine binding site 
able to modulate chloride channel function and/or kinetic 
[31]. In particular, an increased distance between the 
two charged heads of taurine and/or a more distributed 
positive charge for the replacement of the amino group 
with aza-cyclo moieties lead to a decreased potency in 
enhancing gCl [31]. The direct action of taurine on skel-
etal muscle chloride channel was further confirmed by 
two microelectrode voltage-clamp recordings of chloride 
currents sustained by human ClC-1 channel heterolo-
gously expressed in Xenopous oocytes. In these condi-
tions, the in vitro application of 20 mM taurine enhanced 
by 100% the chloride currents and shifted channel acti-
vation toward more negative potentials, an effect that 
likely accounts for the increase in resting gCl observed 
in native fibers [32–34]. This direct modulation adds to 
other possible homeostatic and modulatory roles that 
the high intracellular taurine has on chloride channels. 
However, as anticipated, the acute modulation of gCl 
may require fully or partly functional chloride channels, 
questioning about the real efficacy of taurine in ClC-1 
related myotonic syndromes, especially for those muta-
tions that seriously affect channel expression and protein 
level. Taurine has been tested in patients with myotonic 
dystrophy with encouraging results. In particular acute 
parenteral administrations of taurine allowed to reduce 
membrane excitability evaluated in relation to potassium 
plasma concentration after potassium-enriched infusion, 
suggesting again an action on membrane ionic conduct-
ance. Accordingly, a double-blind oral administration of 
taurine led to a long-term control of myotonic symptoms 
estimated as reduction of electromyographic (EMG) 
discharges and potassium induced-hyperexcitability 
[35–37]. Even taking into account the possible bias deriv-
ing from these small sized trials, the effects of taurine in 
myotonic dystrophy patients suggest alternative modality 
for decreasing membrane excitability. In fact, myotonic 
dystrophy type 1 (DM1) or Steinardt syndrome, is caused 
by expansion of a CTG trinucleotide repeat in the non-
coding region of DM protein kinase with abnormalities 
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in mRNA metabolism and alternative splicing of certain 
genes. In DM1 patients, the abnormal inclusion of alter-
native exons 6B and/or 7A and retention of intron 2 of 
CLC-1 channel gene (CLCN1) gene have been observed. 
These aberrant-splicing, which may also occur in myo-
tonic dystrophy type 2 (DM2) patients, leads to prema-
ture termination codons, with a consistent decrease of 
the mRNA of CLCN1, of ClC-1 protein and consequently 
of gCl [38, 39]. Therefore, the possible modulatory action 
of taurine on other skeletal muscle ion channels has to be 
taken into account.
Taurine and Nav1.4 voltage gated sodium channels
It is feasible to hypothesize a modulation by taurine of the 
skeletal muscle isoform of voltage-gated sodium channel 
(Nav1.4), involved in the generation and propagation of 
action potential and main target of symptomatic anti-
myotonic drugs [37, 40]. The effect of taurine on sodium 
channels of native muscle fibers has been investigated in 
our laboratories by cell-attached patch clamp recordings. 
Taurine has a dual effect. In particular taurine enhances 
the sodium transients elicited by depolarizing test pulses 
close to the threshold for channel activation (test pulse 
to −70/−50  mV), an effect that is likely related to the 
observed shift of the activation curve towards more 
negative potentials. However, taurine reduces sodium 
currents at more depolarized test pulse potentials, with 
a 50% inhibition of the maximal peak sodium current 
observed at 10 mM taurine. In parallel, a left-shift of the 
steady-state inactivation curve has been observed, indi-
cating the ability of taurine to stabilize the blocked chan-
nels in the inactivated state [34, 41 Desaphy and Conte 
Camerino, unpublished observation]. This peculiar effect 
of taurine on Nav1.4 channel is similar to what has been 
observed on cardiac sodium currents [42, 43] and under-
lines a complex action of the amino acid on sodium chan-
nel gating and kinetic. Our extensive structure–activity 
relationship studies of inhibitors of Nav1.4 channel allow 
to predict that the anesthetic-like action of taurine is 
mediated by the amino group, a main pharmacophore 
moiety in sodium channel blockers [44–47]. The dual 
ability of taurine to open chloride channels and to block 
sodium channels envisages a greater therapeutic action 
of the amino acid in myotonic states related to gain-of-
function mutations of sodium channels, such as Sodium 
Channel Myotonia and Paramyotonia Congenita. The 
verification that taurine is able to compensate mutation-
related biophysical alterations of Nav1.4 channels will 
be helpful at this regard, and is part of future projects of 
our laboratory. For the moment, the action of taurine on 
sodium channels can account for the antimyotonic effect 
in conditions where chloride channels are defective or 
dysfunctional [35, 36]. In line with this, the mechanism of 
taurine action on Nav1.4 sodium channels deserves to be 
further investigated since it may better support its phar-
macological potential and its clinical use in hyperexcit-
ability muscle disorders (Table 1).
Role of proper taurine intramuscular level 
for excitation–contraction coupling and muscle 
performance
The ability of skeletal muscle to concentrate taurine 
against gradient pushed toward a better understand-
ing of its physiological role. Adult rats were chronically 
treated with guanidinoethane sulfonate (GES), an inhibi-
tor of taurine transporter (TauT) to induce a reduction of 
taurine content in skeletal muscle. We found that a 50% 
reduction of taurine in EDL muscle leads to a marked 
decrease in gCl, and to a parallel enhancement of sar-
colemmal excitability, disclosing the ability of taurine 
level to exert a physiological control on chloride chan-
nel function and sarcolemmal stability [48]. The mecha-
nism underling this effect is not clear yet, but we cannot 
rule out the ability of taurine to modulate ClC-1 chan-
nel function via a fine-tuning of a calcium-dependent 
phosphorylation-signaling pathway, as discussed below. 
In line with the described ability of taurine to control 
calcium homeostasis in both skeletal muscle and cardiac 
tissue [1, 4], we found a marked alteration of mechani-
cal threshold, i.e. the voltage at which muscle fiber 
contracts in response to depolarizing voltage steps, in 
taurine-depleted EDL myofibers. Mechanical threshold 
depends on the kinetic of calcium release from and reup-
take by sarcoplasmic reticulum, also in relation to basal 
cytosolic calcium concentrations. Taurine depleted EDL 
muscle fibers contract at more negative potentials with 
respect to normal ones, implying an impact of GES treat-
ment on calcium handling [48, 49]. Both the decrease in 
gCl and the shift of mechanical threshold toward nega-
tive potentials were rapidly reverted by in vitro applica-
tion of millimolar concentration of taurine. Actually, 
depleted muscles showed a higher than normal sensi-
tivity to exogenous taurine with respect to normal ones 
[48], further corroborating the link between the observed 
alterations and the taurine level. The contractile proper-
ties and fatigability of EDL muscles depleted of taurine by 
a GES treatment were investigated by Bakker’s group. It 
was found that the treatment with GES decreases mus-
cle taurine levels to <40% of controls and decreases the 
peak twitch force of EDL muscles by 20%. Also, GES-
treated muscles develop a lower force in force–frequency 
relationship and show a slower time to fatigue, likely in 
relation to the lower metabolic demands of the weaker 
muscles [50]. Primary information about the long-term 
effect of taurine in skeletal muscle and, consequently, 
of potential usefulness of its exogenous administration 
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derives from studies on mice in which the TauT was 
genetically knocked out [6, 14–16]. TauT knockout mice 
(TauT−/−) show more than 90% decrease in taurine con-
tent in both muscle and heart and are characterized by 
a marked decrease in exercise performance in exhaus-
tive training models. Although the force of isolated mus-
cle has not been measured in these TauT−/− mice, clear 
abnormalities of muscle structure have been found, 
including signs of atrophy and muscle necrosis. Addi-
tionally, the muscles of TauT−/− mice have a shift of 
metabolism toward the glycolytic pathway, especially in 
condition of exercise; this has been related to a dysfunc-
tion in mitochondrial function and in fatty acid oxida-
tive pathways [51]. In parallel, taurine deficiency leads to 
cardiomyopathy characterized by remodeling of ventric-
ular cardiomyocytes, ultrastructural damages of myofila-
ment and mitochondria, and overexpression of markers 
of heart failure, such as atrial natriuretic peptide, brain 
natriuretic peptide and beta-myosin heavy chain [15, 16].
It is therefore evident that taurine is essential to main-
tain muscle performance and excitation–contraction 
coupling; however the mechanism for these actions is 
still unclear. An in vitro study of Berg and Bakker clearly 
demonstrated the ability of taurine to increase the accu-
mulation of calcium into sarcoplasmic reticulum (SR) in 
isolated skinned myofibers by 35%, an effect that accounts 
for the greater depolarization-induced contraction of 
fiber exposed to 20  mM taurine. This in spite taurine 
slightly reduces the sensitivity of contractile apparatus 
to calcium [52]. Interestingly, a recent study demon-
strated that a prolonged exposure to 10–20 mM taurine 
increases the rate of calcium uptake in both type I and 
type II human myofibers; an action within the SR lumen 
has been proposed. An increase in contractile sensitivity 
to calcium was also observed but exclusively in type I fib-
ers [53]. These results reinforce the original data of Huxt-
lable and Bressler about the ability of taurine to stimulate 
calcium uptake by vesicles of SR [13]. Recent insight into 
the role of taurine in skeletal muscle has been obtained 
by the group of Hayes, who supplemented rats with tau-
rine and evaluated the outcome on various functional 
parameters [54]. Taurine supplementation significantly 
increases the amino acid content in skeletal muscle, with-
out any adaptive change in TauT activity; in parallel an 
increase in force and a greater resistance and recovery 
after fatigue have been observed. These changes were 
paralleled by an increase in calsequestrin1, the calcium 
binding protein that works to maintain high amounts of 
calcium in the cysterna of SR. This suggests that taurine 
supplemented muscle can store a greater quantity of cal-
cium with a consequent greater calcium availability for 
contraction. However, the involvement of sarco/endo-
plasmic reticulum calcium-ATPase (SERCA) remains 
to be better clarified. A decrease in markers of oxidative 
stress was also found, indicating that taurine may help 
to control activity-related oxidative stress [48]. In sup-
port to this view, a recent report by Silva et  al. showed 
that a daily treatment of rats with 300 mg/kg taurine for 
2 weeks protects muscles against in vivo eccentric exer-
cise damage, such as downhill running [55]. In particu-
lar taurine reduced protein carbonylation or oxidized 
thiols, without increasing the expression of endogenous 
anti-oxidant pathways, such as superoxide dismutase or 
catalase [55]. Sugiura et  al. similarly found that taurine 
administration before strenuous exercise reduces mus-
cle DNA damage likely via down-regulation of inducible 
nitric oxide synthase (iNOS) and consequent reduction 
of nitrosative inflammation [56]. The protective effects 
of taurine supplementation are due to a long term mod-
ulatory effect, likely in relation to its muscle uptake and 
intracellular levels. In fact acute in  vitro application of 
physiological concentrations of taurine to isolated mouse 
soleus muscle, does not increase muscle contractile per-
formance in term of force, fatigue resistance and recovery 
and does not exert any synergistic action when associated 
with caffeine [57]. Despite the authors suggesting a lack 
of ergogenic benefit by acute taurine, it is important to 
underline that slow twitch soleus muscle is characterized 
by high intracellular taurine content [58, 59], predicting 
its lower dependency on extracellular concentrations. 
Accordingly, we have shown that a chronic treatment 
with taurine to dystrophic mice leads to a minor increase 
of its intracellular content in soleus muscle than in fast 
twitch muscles [59].
Although taurine supplementation enhances exer-
cise performance, its efflux during exercise and/or 
ischemia, with consequent decrease in tissue concen-
tration, can also occur [60, 61]. Whether the loss of 
taurine is a marker of tissue damage or rather a cyto-
protective mechanism against ischemic insult, is still 
matter of debate [60, 62, 63]. The protective effect of 
taurine efflux in the above conditions can be related to 
the need to osmotically balance, along with water move-
ment, the increase of by-products of metabolism in the 
myofibers [1, 14]. However a role in the mechanism to 
contrast fatigue can be envisaged. In fact, taurine exerts 
an inhibitory control on channels that couple the meta-
bolic state of the myofiber with membrane excitability, 
such as the ATP-dependent potassium (KATP) chan-
nels and calcium-activated potassium channels [64, 
65]. Taurine blocks skeletal muscle KATP channel by 
binding the channel complex nearby the sulphonylu-
rea receptor [64]. During ischemia–reperfusion injury, 
the opening of KATP are involved in the cytoprotective 
effect of the preconditioning mechanisms, by prevent-
ing the influx of calcium ions and preserving the ATP 
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content of the muscle. The efflux of taurine during exer-
cise and/or ischemia may be required to relief a basal 
inhibitory effect and to enhance the potassium efflux 
and membrane repolarization via the specific channels 
activated by ATP depletion and/or intracellular cal-
cium accumulation. This would exert a protective action 
against exercise-induced fatigue or impairment in mus-
cle performance related to ischemia–reperfusion injury 
[64, 65]. Accordingly, the depletion of taurine induced 
by GES in rat skeletal muscle significantly increases the 
macroscopic resting potassium conductance of about 
80% [48].
Intracellular taurine can also be conjugated in mito-
chondria of extra-hepatic tissues to 5-taurinomethyl uri-
dine that is present in tRNA and modulates the synthesis 
of mitochondrial proteins. Consequently, the fatigue and 
the enhanced oxidative stress observed in myopathic 
states by taurine depletion can also be due to respiratory 
chain inefficiency [4, 51, 66]. A representative scheme 
of the taurine actions in striated myofibers is shown in 
Fig. 3.
Taurine as potential therapeutic muscular agent 
from birth to elderly
The role of taurine for post-natal development of vari-
ous organs depends upon the species-specific ability to 
endogenously synthesize the amino acid. Cats, that criti-
cally depend on exogenous taurine intake, develop seri-
ous impairments during post-natal development if not 
fed with taurine. Although less compelling for humans, 
prematurely born infants are believed to lack the 
enzymes that convert cystathionine to cysteine, and may, 
therefore, become taurine-deficient if not breast-fed. In 
fact taurine is present in mother’s milk and evidences 
are available about potential usefulness of taurine addi-
tion in the formula especially for pre-term births [67, 68]. 
The actual necessity or benefit of this practice has never 
been rigorously studied, and as such, taurine has yet to 
be proven to be important during fetal development, per-
haps via epigenetic and/or organogenesis related mecha-
nisms. Recent focus has been addressed to the potential 
benefit of taurine supplementation in mice during ges-
tational period, especially when mothers are exposed to 
Fig. 3 Representative scheme of the action of taurine in skeletal muscle fiber. It is shown the TauT carrier which works to maintain high intracellular 
taurine level, along with the actions that taurine exerts on membrane channels, sarcoplasmic reticulum, mitocondria and possibly gene expression. 
Putative binding sites for taurine are shown (1) on ClC-1 channel and (2) as local anesthetic drug binding site. Arrows indicate a general stimulating 
action while dotted lines are for inhibitory effects or yet undefined pathways. A pathway for taurine efflux under stress conditions (ischemia, osmotic 
stress, etc.) likely via the volume-sensitive organic anion channel (VSOAC) is also shown.
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low-protein diet, a condition mimicking the low weight 
at birth and related to the risk of developing dysmeta-
bolic states later on [69]. In these conditions taurine pro-
tects pancreas by decreasing islet sensitivity to cytokines 
and shows to have an impact on gene expression and 
“reprogramming” in various tissues, including skeletal 
muscle [70–72].
In support of the pivotal role of adequate taurine level 
for skeletal muscle development, we demonstrated that 
taurine muscle level increases during the first month of 
rat post-natal life [73]. This increase matches the acquisi-
tion of phenotype-specific contractile properties. In par-
ticular in rat fast-twitch EDL muscle it occurs in parallel 
with the post-natal increase in muscle gCl and of ClC-1 
channels expression; i.e. during the acquisition of the 
mature profile [39, 73–75]. Adult levels are likely to be 
attained later, since a proton nuclear magnetic resonance 
(H-NMR) study showed an increase in taurine in differ-
ent rat skeletal muscles from 6 to 18  weeks of age [76]. 
Accordingly, an age dependent increase of taurine as well 
as of other amino acids, has been found in muscle of met-
abolically healthy children (age range 1–15) with respect 
to adults [77].
In agreement with an active role of taurine for muscle 
phenotype acquisition, supplementation of mothers dur-
ing pregnancy and lactation as well as of new-born rats 
results in a higher content of the amino acid in skeletal 
muscle, accompanied by a more rapid development of 
gCl [73]. Whether such an increase is due to a modula-
tory action of taurine on ClC-1 channel or to an effect on 
its gene expression is not known yet. Importantly, a pro-
found alteration in gene expression has been described in 
liver and skeletal muscle of pups that were exposed pre-
natally to low protein diet, while the addition of taurine 
to mothers via drinking water during gestation leads to a 
marked protection [71, 72]. Focusing on skeletal muscle, 
the rescuing effect of taurine did occur for genes involved 
in oxidative phosphorylation and in the tricarboxylic 
acid cycle that were markedly down-regulated in skeletal 
muscle by the low protein diet. Importantly, plasma tau-
rine concentration has been suggested to be a marker of 
fetal well-being and a prerequisite for normal fetal devel-
opment [78]. In line with the important role of taurine 
for skeletal muscle development, the TauT expression 
increases during myogenesis and its gene has consensus 
site for myocyte enhancing factor 2 (MEF2), being there-
fore under strict control of myogenic program [79]. Also, 
taurine has been shown to stimulate myofiber differen-
tiation in  vitro [80]. Although the mechanism through 
which taurine may control gene expression during devel-
opment is not clear yet, it appears to be a necessary factor 
in myogenesis, and perhaps in mitochondrial biogenesis, 
with key role for tissue development (Table 1).
Another condition that may benefit from taurine sup-
plementation is aging. Age-related sarcopenia is accom-
panied by profound changes in hormonal and metabolic 
profile of skeletal muscle. An important alteration in the 
content of various amino acids occurs in human muscle 
specimen with age, as a result of age-related increase in 
proteolysis; in parallel a marked decrease in taurine con-
tent has been observed [81].
Besides sarcopenia, skeletal muscle of aged rats devel-
ops features that are overlapping those observed in tau-
rine depleted muscles, i.e. a marked decrease in gCl and 
a change in calcium homeostasis with a shift of mechani-
cal threshold towards more negative potentials [82, 83]. 
We found by high-performance liquid chromatography 
(HPLC) determination that muscle taurine concentration 
is in fact significantly decreased in muscle of aged rats; 
however the levels can be restored to adult values upon 
the exogenous administration of taurine for 3  months 
(1 g/kg in drinking water) [84]. Importantly, the taurine 
administration counteracts the decrease in gCl and the 
alteration in excitation–contraction coupling of aged rat 
EDL muscle, supporting the key role of the amino acid in 
the alterations observed and the potential beneficial role 
of its supplementation in elderly subjects (Table 1). In the 
EDL muscle of aged rats supplemented with taurine an 
almost complete recovery of the pharmacological sensi-
tivity of gCl to either direct and indirect channel mod-
ulators, such as the enantiomers of p-chloro-phenoxy 
propionic acid and the phorbol esters, respectively, was 
observed. The effect of these latter, along with the ame-
lioration of mechanical threshold observed, discloses the 
ability of taurine to modulate gCl by reducing the phos-
phorylation state of the chloride channel brought about 
by calcium and phospholipid-dependent protein kinase C 
[83, 84]. This offers a unifying mechanism for physiologi-
cal taurine action via calcium homeostasis and modula-
tion of calcium-dependent signaling pathways.
In line with the above observations, TauT−/− mice show 
accelerated senescence, with greater muscular damage 
and endoplasmic reticulum stress due to accumulation of 
misfolded proteins. A central role of calcium mishandling 
has been proposed, along with the interest in maintaining 
adequate taurine level for contrasting aging-related mus-
cle impairments [85].
Taurine and muscular dystrophy
The alteration of calcium homeostasis is a hallmark of 
muscles affected by inherited muscular dystrophy, such 
as in mice with X chromosome-linked muscular dys-
trophy (mdx), the most widely used model for Duch-
enne muscular dystrophy (DMD). It is believed that the 
absence of dystrophin, a protein with a key role for sar-
colemmal integrity and mechano-transduction, leads to 
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sarcolemmal tears and to overactivity of voltage-insen-
sitive cationic channels which enhance passive calcium 
entry, especially during work load [86–88]. This in turn 
leads to both the alteration of excitation–contraction 
coupling and to the activation of degenerative pathways 
[88, 89]. We have found that the EDL muscles of dys-
trophic mdx animals undergoing chronic exercise pro-
tocols, have features resembling taurine depleted ones, 
i.e. a reduction of gCl and a negative rheobase voltage for 
mechanical activation [89, 90]. Dystrophic muscle may 
have a reduced ability in retaining intracellular taurine; 
in fact we observed a trend of a lower than normal tau-
rine muscle concentration in parallel with markedly high 
levels in plasma [89]. Accordingly, other authors found 
that taurine levels fluctuate in mdx muscles in relation 
to the disease phase, with compensatory increases being 
observed after acute degenerative period and glucocorti-
coid treatment [91, 92]. In this frame, taurine seems to be 
a useful marker of the dystrophic state of mdx mice when 
monitored by H1-magnetic resonance spectroscopy 
both in  vivo and ex  vivo, although technical problems 
may still limit the accurate peak resolution for quantita-
tive evaluation [91–95]. In our experiments, the in vitro 
application of millimolar taurine concentrations fully 
restored the alteration of mechanical threshold observed 
in these animals [89]. Interestingly, similar results have 
been obtained upon chronic taurine treatment in exer-
cised mdx mice. The in vivo treatment also significantly 
contrasted the decrease in gCl and lead to a significant 
increase of mouse strength in  vivo, due to an interest-
ing anabolic action of the amino acid in the dystrophic 
animals [90]. As previously mentioned, TauT−/− mice 
are characterized by a marked 80% decrease in exercise 
performance and increased fatigability, a feature that is 
classically observed in the mdx phenotype [6, 14, 90, 96]. 
The role of taurine in muscular dystrophy is also under 
study in Hayes’ laboratory, where a lower expression 
of TauT in mdx mouse muscle has been demonstrated, 
which is not influenced by exogenous taurine adminis-
tration [97], supporting the difficulty of dystrophic mus-
cle to retain taurine. Exercise protocols may differently 
modulate intramuscular taurine concentration, ranging 
from no change to phenotype-dependent decrease, likely 
in relation to the exercise type; however taurine supple-
mentation can enhance exercise performance [60, 61]. 
Due to the impaired mechano-transduction of dystrophic 
myofibers, it would be of interest to evaluate whether the 
exercise protocol in mdx mice can lead to a further dis-
tress in taurine concentration and in TauT expression; 
this is currently ongoing in our laboratory.
Based on first encouraging results, we tested 
the possible advantage to combine taurine with 
α-methylprednisolone, a glucocorticoids currently in use 
in dystrophic patients [58]. A synergistic action of the 
two drugs in enhancing mouse strength and in restoring 
calcium homeostasis was observed, with a normaliza-
tion of mechanical threshold and a reduction of the over-
activity of the cation channels likely involved in abnormal 
calcium entry [58, 86, 98]. The treatment was also associ-
ated with a significant increase in taurine content in fast-
twitch limb muscles, suggesting that dystrophic muscle 
maintains the ability to uptake taurine if adequately sup-
plemented [58]. The synergistic action observed corrobo-
rates a potential interest of taurine as adjuvant therapy 
in steroid-treated patients. This is also supported by the 
evidence that glucocorticoids exert an inhibitory action 
of renal taurine re-uptake, then leading to hypotaurine-
mia, which in turn may have long-term negative effects 
on cardiovascular function [5].
Importantly, the taurine treatment to mdx mice signifi-
cantly reduces the high plasma level of lactate dehydro-
genase, an index of metabolic distress, and it is worth to 
underline that a marked increase in plasma lactate actu-
ally occurs in TauT−/− mice [6]. Therefore taurine can 
also play a role in metabolism in dystrophic muscle, simi-
larly to what observed in exercise-challenged TauT−/− 
mice [51].
Increasing evidences suggest a link between calcium 
homeostasis, oxidative stress and mitochondrial distress 
in muscular dystrophy, leading to reconcile all these 
taurine actions under few main mechanisms, although 
not fully clear yet [99, 100]. As already mentioned, tau-
rine supplementation contrasts the exercise-induced 
increase in oxidative markers, without enhancing the 
level of endogenous anti-oxidant [55]. Other evidences 
support that the sulfonic amino acid is actually incapa-
ble of scavenging the common oxidants, namely, super-
oxide, hydrogen peroxide and hydroxyl radical, which 
instead are the main products of enhanced NADPH oxi-
dase activity in dystrophic muscle [99–101]. However, 
the amino group of taurine can neutralize hypochlorous 
acid, one of the reactive species generated by myeloper-
oxidase-halide system in neutrophils [102]. In that reac-
tion, taurine is converted to taurine chloramine, which 
is less toxic than hypochlorous acid and actually serves 
as a modulator of the immune system also by interfering 
with the production of several pro-inflammatory media-
tors and activation of the transcription factor nuclear 
factor kappa-light-chain-enhancer of activated B cells 
(NF-kB) [102]. In addition, taurine has been proposed to 
directly activate peroxisome proliferator-activated recep-
tor γ (PPARγ) in epithelial cells, a mechanism that may 
account for its protective action against inflammation-
related diabetic retinopathy progression [103]. In con-
sideration of the involvement of chronic inflammation 
and NF-kB derived mediators in dystrophic muscle [87, 
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104, 105], the above immunomodulatory actions of tau-
rine are of value. However, whether the anti-inflamma-
tory and anti-oxidant action contributes to the beneficial 
effect observed in dystrophic animals is not known yet 
and the evaluation of biomarkers in samples of taurine 
treated mdx mice will be useful at this regard. Our pre-
liminary results favor a decrease in superoxide anion for-
mation, measured by dihydroethidium staining, in tibialis 
anterior muscles of exercised mdx mice treated with tau-
rine (De Luca, personal unpublished observations). An 
attractive hypothesis, currently under study in our labo-
ratory, is that taurine may contrast the impaired SERCA 
activity in dystrophic muscle either directly or by reduc-
ing the damaging effect brought about by oxidation and/
or nitrosylation [13, 54, 106]. Interesting recent results of 
Terrill et al. have shown that a chronic administration of 
the cysteine precursor 2-oxothiazolidine-4 carboxylate 
(OTC) markedly decreases the level of thiol oxidation in 
muscles of mdx mice; in parallel an amelioration of force 
and muscle morphology has been observed. Importantly 
the administration was not paralleled by an increase 
in cysteine or glutathione but rather by an increase in 
taurine level. The authors underlined that the decrease 
in taurine content may have a direct causative role in 
enhanced susceptibility to oxidative stress, disclosing 
a novel mechanism for beneficial effect of the classical 
anti-oxidant N-acetylcysteine [107].
Considering the mitochondrial sufferance occurring 
in dystrophic muscle [93], the previously described role 
of taurine for preserving mitochondrial function has to 
be taken into account for further studies. Similarly, the 
potential role of taurine and its chemical chaperone con-
jugate tauroursodeoxycholic acid in contrasting endo-
plasmic reticulum stress in various conditions should be 
considered for the acute and chronic ability of taurine 
to modulate signaling pathways [108, 109]. In addition, 
taurine may improve muscle metabolism by contrasting 
functional ischemia, based on the described vasodilating 
properties [110]. The clarification of the mechanism of 
action and the evaluation of long term safety and efficacy 
also at heart level can add important pre-clinical data to 
plan clinical trials in DMD patients (Table 1).
Taurine and disuse‑related muscle atrophy
Muscle disuse is a general term which describes a con-
dition of inactivity occurring after prolonged bed rest, 
spaceflight and/or aging. The slow-twitch muscles, 
devoted to postural maintenance, are the most affected 
ones, showing a slow-to-fast phenotype transition and 
severe atrophy, both leading to impaired muscle func-
tion. The adaptation of skeletal muscle to different activ-
ity includes changes in the expression of structural, 
metabolic and contractile proteins that fine-tune the 
characteristics of this tissue. The hindlimb unloaded 
(HU) model of disuse in rodents is a widely accepted 
ground-based model that mimics microgravity condition 
and is used to study the mechanisms responsible for the 
disuse-induced modification of skeletal muscle function. 
The soleus muscle of HU rats and mice becomes atrophic 
and experiences a slow-to-fast phenotype transition, 
characterized by an increased expression of the fast myo-
sin heavy chain (MHC) isoform [111, 112]. Along the 
years, the studies on the HU model have shown that vari-
ous proteins involved in the control of sarcolemma excit-
ability, calcium ion homeostasis, energy metabolism, and 
contractile machinery undergo changes in the expression, 
turnover, and activity in accord with the entering of the 
slow muscle into a fast program [111, 113–117]. In par-
ticular, ClC-1 chloride and Nav1.4 sodium channels are 
differently expressed in fast-twitch and slow-twitch skel-
etal muscles, the expression of both being higher in the 
former. Accordingly with the change of phenotype, ClC-1 
channel activity and expression as well as the intracel-
lular resting calcium level in slow-twitch soleus muscle 
are significantly shifted by HU process toward the values 
of a fast muscle, even before the modification of MHC 
expression [111]. Similarly, HU increased sodium cur-
rent density and sodium channel mRNA level in soleus 
muscle fibers [113]. All these changes alter the resist-
ance to fatigue of antigravity muscle fibers, an effect that 
may contribute to the impairment of muscle function, in 
terms of excitability and contraction. A full understand-
ing of the mechanisms of disuse-induced muscle altera-
tions in humans is still incomplete and few molecules 
have been proposed for therapy [118, 119]. However, 
supplementation with essential amino acids and carbo-
hydrates in combination with exercise attenuates muscle 
protein loss in humans exposed to prolonged inactivity 
[120, 121]. Based on these considerations and on our pre-
vious findings about the action of taurine in the modu-
lation of calcium homeostasis and ion channel function 
[34, 41, 49], we focused on taurine as a potential candi-
date to counteract the HU-induced phenotype transition 
and skeletal muscle function impairment [1, 34].
In agreement with a critical role of taurine in pheno-
type-specific cellular function, the concentration of the 
amino acid is twofold higher in soleus compared to EDL 
muscle. The physiological relevance for this phenotypic 
difference is still unknown but various hypothesis can 
be raised based on the essential role of taurine in skeletal 
muscle and its actions in metabolism and phenotype-
dependent properties. Interestingly, our recent findings 
[59] showed for the first time a marked reduction of tau-
rine content in the soleus muscle of HU rat. This mus-
cle loss would be consistent with an original report of 
National Aeronautics and Space Administration (NASA) 
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describing a large excretion of taurine in the urine of the 
astronauts of the APOLLO mission [122]. In spite of the 
reduction of taurine in soleus muscle of HU rats, the 
expression of TauT was unchanged. Indeed, TauT expres-
sion was found to be higher in slow-twitch soleus muscle 
with respect to the fast EDL, and was not reduced dur-
ing HU, suggesting that the intracellular reduction of tau-
rine is not associated with the change of phenotype. In 
addition, our data suggest that TauT activity is efficiently 
maintained during HU, since taurine oral supplemen-
tation fully prevents the loss of taurine content in HU-
soleus muscle. Thus, we hypothesize that the reduction 
of intracellular taurine content during HU is likely due to 
increased taurine efflux. A possible explanation might be 
that taurine leakage compensates for intracellular osmo-
larity changes, which likely occurs due to muscle protein 
degradation and increased catabolism. Accordingly, the 
production of intracellular osmolytes during muscle dis-
use atrophy has been described, which may justify tau-
rine escape in this condition [123–125]. Importantly in 
rats fed with taurine, TauT expression was reduced in 
soleus muscle, suggesting a negative feed-back regula-
tion as a mechanism to control taurine intracellular level. 
As anticipated the TauT expression is under control of 
MEF2, a determinant of slow-fiber phenotype [79], thus 
it is tempting to speculate that TauT expression after 
taurine supplementation can be reduced by a mecha-
nism involving a complex cross-talk between taurine and 
ClC-1 modulation during the phenotype transition.
Our findings also highlighted that taurine supplemen-
tation in HU rats has preserved resting gCl and resting 
cytosolic calcium level together with the slow MHC phe-
notype in the soleus muscle.
However, taurine had little effect on muscle atrophy, 
which is a severe condition occurring during HU as well 
as in various muscle diseases [126]. Indeed, it did not pre-
vent the reduction of muscle-to-body weight ratio and of 
the fiber cross sectional area (CSA), while it partially con-
trasted the expression of atrogin-1 and mostly of muscle 
RING-finger protein-1 (MURF-1), two ubiquitin–protea-
some pathway enzymes, that are strongly up-regulated 
as a result of HU-induced atrophy [127]. Such an effect 
suggests that a longer treatment or a different therapeutic 
schedule of taurine might have protective effect against 
muscle atrophy and might be useful to reach a complete 
muscular recovery. However complex mechanisms con-
trol the relative expression of atrogin and MURF-1 in 
skeletal muscle under various insults [79, 128] and fur-
ther experiments are needed (Table 1).
Taurine and human skeletal muscle
Taurine has limited use in clinical settings although 
human use has been considered for specific diseases such 
as non-insulin dependent diabetes and related disorders, 
to treat alcohol withdrawal, congestive heart failure and 
arrhythmias, rheumatoid arthritis and other chronic 
inflammatory states, seizure disorders, and liver related 
disorders [19, 102, 129]. In Table  2 is a brief report of 
some clinical studies related to taurine supplementa-
tion, with relative dosages and outcomes. Most of them 
focused on diabetes mellitus, insulin resistance and dia-
betic complications, based on the rationale that plasma 
taurine concentration is reduced in patients with insulin-
dependent diabetes mellitus (IDDM) [129–136]. Taurine 
was indicated in addition to specific drugs. Other clinical 
studies tested taurine in congestive heart failure, hyper-
tension, inherited succinic semialdehyde dehydrogenase 
deficiency, obesity or its supplementation in aged indi-
viduals [137–143].
A part for the use in myotonic dystrophy patients [35–
37], the potential therapeutic role of taurine for skeletal 
muscle disorders has yet to be verified in clinical set-
tings. In fact, most of the studies about the role of tau-
rine for skeletal muscle physiology and its potential in 
pathological conditions have been carried out in animal 
models. In these conditions taurine depletion or sup-
plementation are directly correlated with changes in the 
amino acid content in skeletal muscle, which facilitate 
the drawing of conclusion about amino acid action and 
potential. However, few studies have been conducted in 
humans, and some contradictory reports are available, 
questioning about the actual usefulness of taurine sup-
plementation or on its mechanism of action. Apart for 
the age-related changes reported in the previous para-
graphs, one of the main issue concerns the modulation of 
taurine concentration in adult skeletal muscle under con-
ditions of exercise and/or metabolic distress. Galloway 
et al. [144] demonstrated that taurine supplementation to 
exercised healthy adults leads to a marked increase in the 
amino acid plasma level that however is not paralleled, 
after 7  days of supplementation, by an increase in skel-
etal muscle. They proposed that intramuscular taurine 
concentration is tightly regulated and that high plasma 
level may actually work to reduce TauT activity in order 
to maintain constant the amino acid level. Therefore, 
even chronic oral taurine supplementation may cause 
less increase in human muscles than in rodent ones, and 
the observed muscle effects could be due to extracellular 
taurine actions. In addition, plasma levels are also tightly 
regulated via overexpression of TauT in kidney, which 
may also show specie-specific regulatory pathways [145, 
146].
The dose is another important issue. In fact murine 
pre-clinical studies often require about tenfold higher 
concentration that in human trials; by the way this has 
to match the endogenous high level of taurine in target 
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organs. In addition, an accurate muscle exposure to tau-
rine after oral ingestion requires a careful assessment of 
the pharmacokinetic profile that has not been extensively 
evaluated in humans. In line with Galloway et al. [144], a 
single oral dose of 4 g in healthy volunteers allows to get a 
maximal plasma peak in about 1.5 h and showed an half-
life of 1 h with a first-order kinetic clearance; this is in line 
with kidney being the main organ regulating taurine level 
[147]. Generally the daily dose of taurine ranges between 
3 and 6  g; consequently its fast kinetic can account for 
some of the puzzling data obtained, suggesting the need 
of a more careful determination of the optimum dose. It 
is important to underline that most of the available evi-
dences focus on the usefulness of taurine supplementa-
tion in sustaining muscle function in trained individuals. 
Balshaw et al. have recently evaluated the outcome of 1 g 
taurine ingestion, evaluated in blind against placebo, on 
running performance of trained middle-distance run-
ners. They described a modest, although significant, 
increase in performance in the taurine-treated group, 
without any change in metabolism parameters [148]. 
The authors claimed that a similar improvement of 
performance after taurine ingestion, without changes in 
oxygen uptake or plasma lactate, has been found in other 
studies [144]. Taurine muscle levels were not assessed, 
thus the correlation between taurine effect and a specific 
muscle action is rather indirect. Accordingly, they specu-
lated about alternative potential mechanisms, such as the 
action of taurine at muscle membrane level, in prevent-
ing taurine drop during exercise or rather an effect on 
neuronal function.
In another study, a combination of taurine (2  g) and 
branched-chain amino acids three times a days for 
2  weeks before eccentric exercise, plus 4  days after, has 
been tested in healthy untreated volunteers. The eccen-
tric exercise protocol consisted of repeated sets elbow 
flexion at 90° to an extended position, finally leading 
to uncontrolled damaging stretch. The combination 
exerted a greater protection against muscle damage and 
delayed-onset muscle soreness than single administra-
tions, although no detailed investigation has been done 
to clarify the mechanism of action and/or the amino 
acid level into the muscle [149]. Similarly, da Silva et al. 
have recently described the ability of 14  days taurine 
Table 2 Clinical use of taurine in different pathophysiological conditions
References Patients Dose (g/day or mg/kg) Duration Result
Franconi et al. [130] IDDM (Diabetes  
mellitus type 1)
1.5 g 90 days No effect
Elizarova and Nedosugova 
[131]
IDDM 1 g 30 days Glucose metabolism and 
trygliceride level improved
Chauncey et al. [133] NIDDM (DM type 2) 3 g 4 months Plasma taurine level increased
Brøns et al. [134] Overweight non-diabetic 1.5 g 8 weeks No effect
Xiao et al. [136] Overweight non-diabetic 3 g 2 weeks Insulin sensitivity improved
Nakamura et al. [132] NIDDM with  
microalbuminemia
3 g 12 months No effect
Moloney et al. [135] IDDM 1.5 g 2 weeks Endotelium-dependent reac-
tion improved
Gonzales-Contreras et al. 
[142]
Cholestasis by  
parenteral nutrition
~25 mg/kg/day ~50 days Hepatoprotection with reduc-
tion of AST, ALT and GGT
Rosa et al. [143] Obesity 3 g/day 8 weeks Increase in plasma levels of 
taurine and adiponectin; 
reduction of inflammatory 
markers
Pearl et al. [141] Succinic semialdehyde 
dehydrogenase deficiency 
(efficacy, safety and  
tolerability)
50–200 mg/kg/d (age 
range 12 years)
13 months (mean time 
from 3 to 50)
No significant effects
Tolerability issues at highest 
doses
Fujita et al. [139] Hypertension 6 g 7 days Systolic and diastolic pressure 
improved
Azuma et al. [138] Congestive heart failure 6 g 4 weeks Heart parameters improved
Bergamini et al. [137] Epilepsy 200 mg–21 g Various Seizure frequency reduction
Durelli et al. [36] Dystrophic myotonia 6–10 g 6 months Myotonic symptoms improve-
ment
Dunn-Lewis et al. [140] Elderly 500 mg in multinurtient 
supplement
4 weeks Physical function improved
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administration to increase strength of the elbow flexor 
subjected to eccentric exercises in young adult males; in 
parallel, markers of oxidative stress were reduced, with-
out increase in endogenous anti-oxidant expression nor 
changes in inflammatory markers. Again muscle taurine 
level were not determined [150]. Therefore the available 
evidences do not allow to conclude about the ability of 
supplemented taurine to actually increase its muscle 
level in adult healthy and trained individuals, suggest-
ing alternative modality of action, i.e. at neuromuscular 
system. However, it cannot be ruled out that taurine sup-
plementation may effectively enhances muscle taurine 
levels in conditions characterized by more dramatic fluc-
tuation of its content. This applies to postnatal develop-
ment and aging, and mostly to pathological conditions 
such as muscular dystrophy and disuse-related muscle 
dysfunction (Table  1) [151]. More direct evidences in 
humans and patients will be helpful, in order to better 
correlate the effect of exogenous administration of tau-
rine with the ability of residual muscle tissue to uptake 
the right amount, or rather to disclosure taurine actions 
independent on its intracellular levels [145]. In addition, 
an inter-individual variation in plasma increase of tau-
rine after supplementation may occur in relation to both 
nutritional state, age, drug interaction, while gene poly-
morphism in taurine transporter or modulation of its 
function and/or expression by cell metabolic state or acti-
vation of transcription factors may affect the actual level 
of taurine being transported into the myofibers [134, 146, 
152–154]. Hence caution should be taken when conclud-
ing about lack of taurine usefulness for human muscular 
system without an adequate control of all variables.
Conclusion
We herein summarized the results obtained in about 
30 years of research on taurine and skeletal muscle by us 
and other research groups. Taurine is far from themes of 
fashion science or from immediate interest in innovative 
drug development by Pharma Companies. Nevertheless 
the reason for such a long interest is that taurine acquired 
over the years a special appeal for its puzzling and multi-
ple effects. We underlined the ability of taurine to control 
the function of ion channels and consequently membrane 
excitability as well as calcium homeostasis and excitation–
contraction coupling. It has been highlighted that novel 
evidences are emerging regarding taurine mechanism of 
action, ranging from modulation of muscle metabolism 
to control of gene transcription, as well as in the specie-
specific mechanisms underlying its intracellular levels 
in both chronic and acute conditions. These make the 
research on the topic “taurine and skeletal muscle” a con-
tinuous source of novel and exciting results allowing to 
renew the enthusiasm and novel working hypotheses. The 
wide and interconnected effects observed support a key 
role of the amino acid to ensure a proper muscle function 
and reinforce its interest as therapeutic agent in various 
inherited and acquired muscular disorders. The avail-
able evidences favor a greater effect of taurine in diseased 
condition accompanied by alterations in taurine concen-
tration in muscle; similar benefit can occur in conditions 
where fluctuation in taurine level take place such as exer-
cise, protein content in diet or post-natal development. 
Both acute and chronic effects of taurine supplementa-
tion are feasible, and likely occur with different time-scale 
although similarly interesting and important. Although 
a careful distinction has not been made, it is predictable 
that acute effects of taurine are better appreciable in sit-
uations of rapid fluctuations such as exercise, or when 
involving direct modulation of ion channel, or on mus-
cles that are more dependable of external taurine such as 
fast-twitch ones. In parallel, chronic taurine effects, likely 
accompanied by changes in intracellular content, could be 
of value for long term control of neuromuscular function 
in progressive conditions, such as muscular dystrophy 
and disuse or aging-related dysfunction. At this regard 
more evidences are necessary to better understand the 
interest of taurine for ensuring a proper muscle function 
in human other than in animals. Consequently, a more 
clinically-oriented research will help to support the inter-
est of taurine as novel and safer therapeutic approach of 
rare inherited muscle diseases and other myopathic states.
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